vTv Therapeutics Inc. Class A Common Stock (VTVT)

FairStock Score: 16/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I begin with the business, not the story. vTv Therapeutics is a 26-person biotech developing oral small molecules, led by cadisegliatin in Phase III for type 1 diabetes. That is a promising but binary pipeline: if approved, it could matter; today there is no approved product and no durable revenue stream. The filed figures show losses in each of the last four years, which is why FairStock assigns no Peter Lynch category. In fiscal 2025, the year ended 2025-12-31, net loss was $27.0M. In fiscal 2024, net loss was $18.5M on $1.0M of revenue. In fiscal 2023, net loss was $20.3M. More recently, in fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $36.8M and net income was $24.1M. But in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was not available and net loss was $13.1M. That swing does not give me confidence in stable earning power. At the close on 2026-10-13, the price was $28.23 and market cap $141.8M. FairStock calculations show P/E -39.21, P/B 4.45, ROE -15.80%, ROCE -10.14%, TTM FCF -$16.8M, and FCF yield -11.8%. Its Piotroski F-Score is 4/9 and Altman Z-Score is 6.85, while FairStock Score is 16/100. A low beta of 0.21 and no dividend do not offset the cash burn. Without profits or a wide moat, I cannot call this a Graham bargain. It is a speculative clinical bet priced on future hopes rather than present numbers.

In plain English: vTv Therapeutics is a small healthcare company that develops oral medicines, mainly a late-stage drug for type 1 diabetes. It has not made steady profits, has been losing money, and brings in little regular revenue. Based on the current numbers, the stock looks expensive compared with its present earnings and cash generation, though a successful drug trial could change that picture.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer